AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$17.05
−2.24%Price chart
Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 2Sep 8
ValuationView details →
P/E (Fwd)
17.2x
EV/EBITDA
12.6x
Market Cap
$5.44B
MomentumView details →
1D Return
−2.24%
YTD Return
+36.19%
RSI (14)
41.8
ValuationView details →
P/E (Fwd)
17.2x
EV/EBITDA
12.6x
Market Cap
$5.44B
RSI (14)
41.8
MomentumView details →
1D Return
−2.24%
YTD Return
+36.19%
SummaryUpdated Jun 1, 2026
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is a specialty and generic pharmaceutical company founded in 2002 and headquartered in Bridgewater, New Jersey. The company went public in May 2018 following its transformation from Atlas Holdings, Inc. Amneal has evolved from a traditional generic drug manufacturer into a diversified pharmaceutical company with operations spanning generic medicines, specialty branded products, and healthcare distribution services. The company operates manufacturing facilities in the United States, India, and Ireland, serving customers globally through a comprehensive portfolio of pharmaceutical products and services.
Similar companies
Latest newsMore news →
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilar platform covering R&D, manufacturing, and commercialization.29d agoAmneal Pharmaceuticals entered into Amendment No. 4 to its term loan credit agreement, creating a $350 million new incremental term loan to partially finance its acquisition of Kashiv BioSciences.30d agoAmneal Pharmaceuticals reported its financial results for the second quarter of 2026, with net revenue of $796 million, GAAP net income of $58 million, and diluted earnings per share of $0.18.41d ago